-
Board Certification
American Board of Internal MedicineAmerican Board of Internal Medicine (Sub: Hematology)American Board of Internal Medicine (Sub: Medical Oncology)Patient Rating
4.9 /5( out of 95 reviews )The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
August 24, 2025SUGAR HOUSE HEALTH CENTERI really like her. She is knowledgeable and cared about me and my health! She took the time to talk to me, my husband and daughter and we felt comfortable and she didn't appear rushed even though we know she is a very busy doctor. I completely trust her to help us make good decisions for my health.
August 18, 2025HUNTSMAN CANCER CENTERExcellent Doctor [TRANSLATED]
August 16, 2025HUNTSMAN CANCER CENTERDr Chalmers is caring, patient and kind. She takes time to answer all of our questions.
August 15, 2025HUNTSMAN CANCER CENTERGood communicator and listener.
July 12, 2025HUNTSMAN CANCER CENTERDr Chalmers is outstanding, I trust her. She cares. She is very intelligent and perceptive in knowing options for my care.
July 03, 2025HUNTSMAN CANCER CENTERDr Chalmers has saved my life. She is intelligent, caring, and listens to my thoughts and concerns. I trust her with my cancer care. treatment.
June 17, 2025HUNTSMAN CANCER CENTERDr Chalmers gave me a great deal of confidence in her experience and knowledge. She was through and explained things in a way I understood.
May 25, 2025SUGAR HOUSE HEALTH CENTERI am extremely fortunate to have her as my oncologist. She is obviously brilliant and exceptionally well educated. I trust her. She is also compassionate and kind.
May 23, 2025HUNTSMAN CANCER CENTERAhhhh my excellent Doctor, very humane and explained my treatment very well. [TRANSLATED]
-
Board Certification and Academic Information
Academic Departments Internal Medicine -Associate Professor (Clinical)
Academic Divisions Oncology
Board Certification American Board of Internal MedicineAmerican Board of Internal Medicine (Sub: Hematology)American Board of Internal Medicine (Sub: Medical Oncology)Education history
Fellowship Hematology and Medical Oncology - Rush University Medical Center Fellow Residency Internal Medicine - Rush University Medical Center Resident Professional Medical Medicine - Drexel University College of Medicine M.D. Undergraduate Dartmouth College B.A. Selected Publications
Journal Article
- Puri S, Malani R, Chalmers A, Kerrigan K, Patel SB, Monynahan K, Cannon L, Blouw B, Akerley W (2023). Keeping a track on leptomeningeal disease in non-small cell lung cancer: A single-institution experience with CNSide(TM). Neurooncol Adv, 6(1), vdad150. ()
- Kerrigan K, Patel SB, Haaland B, Ose D, Weinberg Chalmers A, Haydell T, Meropol NJ, Akerley W (2020). Prognostic Significance of Patient-Reported Outcomes in Cancer. JCO Oncol Pract, 16(4), e313-e323. ()
- Chalmers AW, Patel S, Boucher K, Cannon L, Esplin M, Luckart J, Graves N, Van Duren T, Akerley W (2019). Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. Target Oncol, 14(4), 417-421. ()
- Chalmers A, Cannon L, Akerley W (2018). Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib. Oncologist, 24(7), 963-972. ()
Editorial
- Chalmers AW, Patel SB, Akerley W (2018). Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care? J Thorac Dis, 10(3), 1198-1200. ()
Letter
- Chalmers A, Akerley W (2017). Retrospective, Multi-Institutional Analysis of Sequential Treatment of Brain Metastases in Treatment-Naïve, Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer Should Not Define the Standard of Practice. [Letter to the editor]. J Clin Oncol, 35(20), 2340. ()
-
News & Podcasts
Huntsman Cancer Institute News
( out of 95 reviews )